Tempus

Tempus is a technology company leading the adoption of #AI to advance precision medicine.

[Tempus @TempusAI]

@JaddSaad Hi, Jad, thank you for bringing this to our attention. I'm sorry to hear that you are experiencing issues. We have sent you a direct message to learn more and best help the situation.

[Tempus @TempusAI]

Today we announced a strategic collaboration with @bmsnews to support their oncology drug portfolio.

We also announced a strategic collaboration with Bristol Myers Squibb and @pathos to advance drug discovery in Alzheimer’s disease.

Collectively, this makes BMS one of our largest data and modeling customers. Through this collaboration, BMS researchers will be able to train advanced AI models using de-identified data to surface breakthroughs and increase the probability of success when developing therapies for both cancer patients and those suffering from Alzheimer’s disease.

Read on: https://t.co/MSyRsIcbSb & https://t.co/XLW54byYX8

[Tempus @TempusAI]

Stop by Booths #1068 & 1069 to experience a live demo of Tempus Lens at #ESMO26.

With Lens, quickly find, access, and analyze multimodal de-identified data records and uncover critical insights to accelerate research and innovation.Explore unstructured clinical data and extract nuanced insights.

See Lens in action: https://t.co/QDpucTlOT3

[Tempus @TempusAI]

Tempus delivers insight generation at scale.

Our comprehensive, AI-powered platform supports every stage of drug development—from discovery through commercialization.

Heading to #ESMO26? Visit Booths #1068 & #1069 to connect with our team and explore our latest innovations.

Learn more: https://t.co/tWA0gHIeID

[Tempus @TempusAI]

Join us at #ESMO26 as we showcase novel clinical research revealing meaningful insights in cancer biology, treatment response, and patient outcomes.

Visit us at booth #1068 & 1069 to experience live demos of our AI-powered technology and new product offerings designed to advance drug discovery and development.

Learn more: https://t.co/09xX8xjhUo

[Tempus @TempusAI]

"Managing the information became as exhausting as managing the illness itself."

For Laura, Chief Commerical Officer at Tempus, and her daughter Sophia, navigating a chronic illness meant tracking fragmented data across multiple specialists.

Watch how Olivia, our personal health concierge app, helped them consolidate their health histories, spot symptom patterns, and take back control.

See their full story: https://t.co/v9ETb61Y4A

#DysatunonomiaAwarenesssMonth

[Tempus @TempusAI]

Real-Time Variant Tracker™ (RTVT), is a feature now available as a part of xM (NeXT Personal ® Dx). RTVT delivers an added layer of clarity directly within the standard report clinicians already receive, including variants associated with NCCN guideline-recommended and FDA-approved therapies.

These findings providing immediate, actionable context the moment an associated signal shifts.

[Personalis, Inc. @PersonalisInc]

🚨Today we announced the commercial launch of optional Real-Time Variant Tracker™ supplemental results in the NeXT Personal® molecular residual disease (MRD) test report.

Real-Time Variant Tracker identifies clinically relevant resistance and therapeutically targetable variants over time during NeXT Personal testing, including variants associated with FDA-approved therapies and recommendations in National Comprehensive Cancer Network® (NCCN®) guidelines.

Learn more: https://t.co/XHGCMm188V.

#PrecisionOncology #MRD #ctDNA #Oncology #MRD

[Tempus @TempusAI]

Study presented at #ESMO26, from our collaboration with @pfizer, evaluated more than 60,000 advanced #NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images.

Read on: https://t.co/GsPw5ih824

[Tempus @TempusAI]

We will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026.

The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website, as well as here: https://t.co/nlpK42jUow

[Tempus @TempusAI]

We'll be at #ASCOQLTY26 presenting two abstracts demonstrating how Tempus Next uses agentic care-gap detection and AI-guided oncology care pathways to identify testing gaps and notify care teams.

Stop by our poster sessions or connect with our team at the conference to learn more: https://t.co/UdBYwiDGpI

[Tempus @TempusAI]

We’re looking forward to seeing you at Pathology Visions '26 in San Diego.

Stop by Booth #204 meet with the Tempus team and experience live demos of our digital pathology and AI offerings that enable biomarker prediction and workflow efficiency.

Learn more: https://t.co/ZC9qAv76ht

@dpatweet #PathVisions26

[Tempus @TempusAI]

We're proud to add to our offerings for patients with rare diseases. This offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges and improve the ability to find and interpret answers.

[Ambry Genetics @AmbryGenetics]

Whole Genome Testing is now available from Ambry. Read the press release: https://t.co/MQlrJqCR9m

[Tempus @TempusAI]

The initial days following an advanced cancer diagnosis are critical for treatment planning.

With Tempus Preview, clinicians may access clinically relevant predictions within ~24 hours of sample receipt. These early insights empower clinicians to anticipate targeted treatment pathways and coordinate management plans, without altering standard tissue workflows.

Tempus Preview provides preliminary predictions and treatment should not be initiated until confirmatory NGS results are received.

Learn more: https://t.co/6uW0V0omFz

[Tempus @TempusAI]

"AI-enabled diagnostics... [have] the potential to remove mistakes, errors, and waste that are plaguing the system. And in cancer alone... if we had a system where every patient was on the optimal therapeutic path—eliminating that trial and error, eliminating all the mistakes—I suspect we could save about 100,000 lives a year." -- Tempus CEO @lefkofsky at @WSJ's Future of Health with @Annie_Gasparro

Watch the recording: https://t.co/4GbxAEugQp

[Tempus @TempusAI]

We're honored to be listed on @FortuneMagazine's #FortuneFuture120, which recognizes companies with long-term growth potential and traits such as "the inner dynamism of their culture."

This recognition is a testament to our team's relentless drive to innovate and our unwavering commitment to unlocking the power of precision medicine for patients everywhere.

Read on: https://t.co/oUW84aYi2q

[Tempus @TempusAI]

Attending #WorldADC in San Diego? Attend our live session featuring our Senior Director of Computational Discovery Science, Radia Johnson, Ph.D., as she shares how we use multimodal real-world data, organoid screens, and AI to improve target selection and test findings against patient outcomes.

Schedule a meeting with the team: https://t.co/uXJOtrlb7l

[Tempus @TempusAI]

Today we announced an expanded collaboration with both @moderna_tx and @Merck to support the potential commercialization of intismeran autogene, a novel individualized neoantigen therapy.

Tempus will deliver advanced NGS sequencing and sample collection workflows, combining our clinical infrastructure with mRNA innovation to help bring personalized cancer vaccines to patients at scale.

Read on: https://t.co/kSdclhaFFq

[Tempus @TempusAI]

"The hardest part of outcomes research isn't running the final analysis — it's getting from a research question to a finalized protocol without losing weeks to study design iterations."

Watch as Adrienne Brackey, MS, a Senior Data Scientist at Tempus, uses Lens, our AI-enabled analytical program, to pressure-test a study design in minutes — all while outcomes stay blinded — and finalize the protocol in record time.

Request a demo now: https://t.co/NVuQ8Myf7c

[Tempus @TempusAI]

October is #BreastCancerAwarenessMonth, a time to honor the strength of each individual facing a diagnosis and to reflect on the power of equipping physicians with meaningful insights when decisions matter most.

When Romy was diagnosed with triple-negative breast cancer, Tempus genomic testing helped arm her physician with insights that led to a targeted combination of immunotherapy and chemotherapy.

She now has no evidence of disease.

Learn more about Romy's story: https://t.co/220nxCwXF2